Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
6.22
+0.04 (0.65%)
At close: Jul 6, 2026, 4:00 PM EDT
6.42
+0.20 (3.22%)
After-hours: Jul 6, 2026, 6:27 PM EDT
Silo Pharma Revenue
Silo Pharma had revenue of $18.03K in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $72.10K. In the year 2025, Silo Pharma had annual revenue of $72.10K.
Revenue (ttm)
$72.10K
Revenue Growth
n/a
P/S Ratio
90.39
Revenue / Employee
$24,034
Employees
3
Market Cap
6.75M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 72.10K | - | - |
| Dec 31, 2024 | 72.10K | - | - |
| Dec 31, 2023 | 72.10K | - | - |
| Dec 31, 2022 | 72.10K | 838.00 | 1.18% |
| Dec 31, 2021 | 71.26K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xenetic Biosciences | 3.19M |
| XTL Biopharmaceuticals | 968.00K |
| Addex Therapeutics | 136.51K |
| AIM ImmunoTech | 94.00K |
| Pulmatrix | 3.00K |
SILO News
- 7 days ago - Silo Pharma engages Resyca to conduct a robustness study for SPC-15 delivery - TheFly
- 7 days ago - Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request - GlobeNewsWire
- 13 days ago - Silo Pharma reports positive stability data for stress treatment SPC-15 - TheFly
- 13 days ago - Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial - GlobeNewsWire
- 18 days ago - Silo Pharma regains compliance with Nasdaq min bid price requirement - TheFly
- 18 days ago - Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 4 weeks ago - Silo Pharma Inc trading halted, news pending - TheFly
- 2 months ago - Silo Pharma files provisional patent for ibogaine-based therapeutics - TheFly